Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma.
Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgraeber V, Kraxner A, Keshelava N, Bechter O.
Munoz-Couselo E, et al. Among authors: martin n.
Cancer Res Commun. 2025 Feb 3. doi: 10.1158/2767-9764.CRC-24-0601. Online ahead of print.
Cancer Res Commun. 2025.
PMID: 39895413